Uremic Pruritus Market Research Report 2030 | Uremic Pruritus Market Trends | DelveInsight

Uremic pruritus or more accurately termed ‘chronic kidney disease-associated pruritus’ (CKD-aP) remains a frequent and compromising symptom in patients with advanced or end-stage renal disease. The pathogenesis of CKD-aP remains obscure. Parathormone and histamine as well as calcium and magnesium salts have been suspected as pathogenetic factors. Newer hypotheses are focusing on opioid-receptor derangements and micro-inflammation as possible causes of CKD-aP, although until now this could not be proven.

DelveInsight's "Uremic Pruritus (UP) Market Insights, Epidemiology, and Market Forecast 2030" report delivers an in-depth understanding of the Uremic Pruritus (UP), historical and forecasted epidemiology as well as the Uremic Pruritus (UP) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


Geography Covered

The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan

Request for a free sample copy of the report: https://www.delveinsight.com/sample-request/uremic-pruritus-market

Uremic Pruritus (UP) Disease Understanding and Treatment Algorithm

Uremia refers to excessive urea in the blood, and occurs when both kidneys stop working (renal failure). Pruritus, or itch, is a common problem for patients with chronic renal failure or end stage renal disease. It affects about one-third of patients on dialysis and is more common with haemodialysis than continuous ambulatory peritoneal dialysis (CAPD).

Uremic pruritus is characterized by daily bouts of itching that tend to worsen at night and may prevent sleep. The itch may be generalised or localised to one area, most often the back, abdomen, head and /or arms. In haemodialysis patients, the pruritus is lowest the day after dialysis and peaks 2 days afterwards. The skin may appear normal or dry (xerosis), with few to numerous scratch marks and/or picked sores.

The DelveInsight Uremic Pruritus (UP) market report gives a thorough understanding of the Uremic Pruritus (UP) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment. 

Uremic Pruritus (UP) Epidemiology  

The Uremic Pruritus epidemiology division provide insights about historical and current Uremic Pruritus (UP) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Key Findings

· Approximately 15% of the adult population in the United States, or 30 million people, suffer from CKD, with an estimated 50% in stages III–V. Of the patients diagnosed with stage III–V CKD, approximately 25% suffer from moderate-to-severe pruritus.

The Uremic Pruritus epidemiology covered in the report provides historical as well as forecasted Uremic Pruritus (UP) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030. 

Click here and get access to free sample copy of our report.

Uremic Pruritus (UP) Drug Chapters

Expected launch of SK-1405 (Sanwa Kagaku Kenkyusho), Nalbuphine ER (Trevi Therapeutics), MR13A9 (Kissei Pharmaceutical), and Difelikefalin/CR845 (Cara Therapeutics/Enteris BioPharma), LT5001 (Lumosa Therapeutics) shall fuel the growth of the market during the forecast period, i.e., 2020–2030.

Drug chapter segment of the Uremic Pruritus (UP) report encloses the detailed analysis of Uremic Pruritus (UP) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.

Uremic Pruritus (UP) Market Outlook

Clinicians and investigators have tested numerous topical and systemic treatments for pruritus. In general, most of the published data regarding treatment of uremic pruritus either are retrospective or underpowered prospective studies; therefore, recommended treatment regimens remain largely based on expert opinion. Here, the most common available therapies for uremic pruritus have been described below.

Pruritus may be extremely vexing at times and difficult to control. Therapeutic options in CKD-aP are, however, limited. Most studies on this symptom are not reliable because of inadequate documentation of patient’s characteristics, concomitant diseases, therapeutic measures taken, and often very low case numbers. Moreover, effects that might be statistically significant may not necessarily be clinically relevant and vice versa.

The Uremic Pruritus (UP) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Uremic Pruritus (UP) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. 

According to DelveInsight, Uremic Pruritus (UP) market in 7MM is expected to change in the study period 2017-2030.

Download sample pages: https://www.delveinsight.com/sample-request/uremic-pruritus-market

Visit our repository of reports: https://www.delveinsight.com/report-store.php

 

 

Comments

Post a Comment

Popular posts from this blog

Tenosynovial Giant Cell Tumors (TSGCTs) Market Research Report 2030 | Tenosynovial Giant Cell Tumors (TSGCTs) Market

Image
Tenosynovial Giant Cell Tumors   are a type of neoplasm that affects synovial-lined tendon sheaths, synovial joints, and surrounding soft tissue. Locally aggressive benign tissue lesions are defined by synovial lining inflammation in joints and tendons. Overexpression of the colony-stimulating factor 1 receptor is thought to cause these tumors to form. Giant cell tumors of the tendon sheath (GCTTS), pigmented villonodular tumors (PVNTS), extra-articular pigmented villonodular tumors of the tendon sheath, and localized or focal nodular synovitis are all terms used to describe TSGCTs. Tenosynovial Giant Cell Tumors Causes Translocation is an alteration to a chromosome that causes Tenosynovial Giant Cell Tumors. A chromosome segment breaks off and moves around. The cause of these translocations is unknown. The genetic code for making proteins is stored on chromosomes. A protein termed colony-stimulating factor 1 is produced in excess due to the translocation (CSF1). This protein attracts
Read more

Functional Dyspepsia Market Research Report 2030 | Functional Dyspepsia Market

Image
  Functional dyspepsia   is a term for recurring signs and symptoms of indigestion that have no apparent cause. Functional dyspepsia is also called non-ulcer stomach pain or non-ulcer dyspepsia. It's not clear what causes functional dyspepsia. Doctors consider it a functional disorder, which means that routine testing may not show any abnormalities. Hence, it is diagnosed based on symptoms. Functional Dyspepsia Signs and Symptoms  Functional dyspepsia is common and can be long-lasting — although signs and symptoms are mostly intermittent. These signs and symptoms resemble those of an ulcer, discomfort in your upper abdomen, often accompanied by bloating, belching, and nausea, An early feeling of fullness (satiety) when eating, Pain in the stomach that may sometimes occur unrelated to meals, or maybe relieved with meals. Functional Dyspepsia Epidemiology According to an article by Madisch et al. (2018), Functional Dyspepsia is one of the common functional disorders, with a prevalenc
Read more

Fibrodysplasia Ossificans Progressiva Market Research Report 2030 | Fibrodysplasia Ossificans Progressiva Market

Image
  Fibrodysplasia ossificans progressiva   is a disorder in which the skeleton, muscles, and connective tissues, such as tendons and ligaments, are replaced by bone (ossified). This position was to lead to the formation of the bones of the skeleton (extra-skeletal or heterotopic bone) that constrains movement. Fibrodysplasia ossificans progressiva Causes Fibrodysplasia ossificans progressiva is called a mutation in the ACVR1 gene. This gene is involved in bone growth and development. Mutations, and the possibility of a disorderly development. The gene can be inherited from a parent, but in most cases, the, is a new mutation, a person with a less-than-a family history of the disease. As a parent, they have a 50% chance of passing it on to their children. Fibrodysplasia ossificans progressiva Sign and Symptoms The  Fibrodysplasia ossificans progressiva  symptoms begin in the first decade of life with episodes of painful inflammatory soft tissue swellings. Gradually, there occurs restricti
Read more